Phaseline

Targets › CD38

CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1): drug programs, companies and trials

14 programs from 14 companies in 315 trials: 164 Phase 2, 62 Phase 1, 55 Phase 3, 34 Phase 4; Oncology, Hematology, Other; next expected readout Nov 2026.

Multifunctional transmembrane glycoprotein able to exert enzymatic activities and also to mobilize calcium, to transduce signals, to adhere to hyaluronan and to other ligands. Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion. (UniProt, P28907)

Open in Phaseline: the race on CD38, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mayo ClinicBCG Solution
Glucagon-like peptide 1 receptor agonist
GLP1R, Ion channels, CD38, OPRM1, PDCD1, CD274Phase 4Pain, Postoperative; Limb Pain, Phantom; Healthy; Respiratory Function Loss …Nov 2026
SanofiH5 Flu IMP 1
Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor
ROCK2, ROCK1, TNFSF4, CD38, IL4RPhase 4RSV Immunization; Diabetes Mellitus, Type 1; Asthma; Dermatitis Atopic …Dec 2026
Johnson & Johnson (Janssen)Daratumumab
Lymphocyte differentiation antigen CD38 inhibitor
CD38Phase 3Multiple Myeloma; Amyloidosis; Hemophilia A With Inhibitor; Microvascular Inflammation - MVI in Kindey Transplant Recipients …Nov 2026
BiogenFelzartamab
Lymphocyte differentiation antigen CD38 inhibitor
CD38Phase 3Antibody-mediated Rejection; Immunoglobulin A Nephropathy (IgAN); Primary Membranous Nephropathy; Graves' Disease …Dec 2026
SinocelltechSCTC21C
anti-CD38 monoclonal antibody
CD38Phase 3Multiple Myeloma (MM); Amyloidosis; Relapsed or Refractory Hematologic MalignanciesFeb 2027
CelltrionCT-P44
anti-CD38 monoclonal antibody
CD38Phase 3Refractory or Relapsed Multiple MyelomaMar 2027
TakedaMezagitamab (TAK-079)
Lymphocyte differentiation antigen CD38 binding agent
CD38Phase 3Immune Thrombocytopenic Purpura (ITP); Kidney Disease; Antibody-Mediated Rejection (AMR)Mar 2028
EMN Trial Office S.r.l. Impresa SocialeIsatuximab-dexamethasone
anti-CD38 monoclonal antibody combined with corticosteroid
CD38Phase 2Relapsed Multiple MyelomaMar 2027
Mao JianhuaSG301
Anti-CD38 monoclonal antibody
CD38Phase 2Nephrotic Syndrome in ChildrenJul 2028
Institute of Hematology & Blood Diseases Hospital, ChinaAnti-CD38 antibody
CD38-targeting monoclonal antibody
CD38Phase 2Immune ThrombocytopeniaDec 2030
CASI pharmaceuticalsCID-103
anti-CD38 monoclonal antibody
CD38Phase 1Chronic Immune Thrombocytopenia; Antibody Mediated RejectionDec 2026
Zhejiang ACEA PharmaceuticalSTI-6129
anti-CD38 antibody-drug conjugate with duostatin tubulin inhibitor
CD38Phase 1Relapsed or Refractory Multiple MyelomaDec 2026
GSKIsatuximab
Lymphocyte differentiation antigen CD38 inhibitor
CD38Phase 1Multiple Myeloma; Newly Diagnosed Multiple Myeloma; Relapsed Refractory Multiple Myeloma (RRMM); Recurrent Multiple Myeloma …Mar 2027
Masonic Cancer Center, University of MinnesotaFT536
Allogeneic NK cell therapy with CD38 knockout and MICA/B chimeric antigen receptor express
CD38Phase 1Gynecologic Cancer; AstrocytomaJun 2027

Conditions

Multiple Myeloma (60) Immune Thrombocytopenia (7) Plasma Cell Myeloma (6) Recurrent Multiple Myeloma (5) Dermatitis Atopic (5) Newly Diagnosed Multiple Myeloma (4) Colitis Ulcerative (4) AL Amyloidosis (3) T-cell Acute Lymphoblastic Leukemia (3) Recurrent Plasma Cell Myeloma (3) Multiple Myeloma (MM) (3) Acute Lymphoblastic Leukemia (3)

Modalities

antibody (6), protein or peptide (4), mixed (2), small molecule (2)

Companies

Takeda (1) Johnson & Johnson (Janssen) (1) Zhejiang ACEA Pharmaceutical (1) Biogen (1) Masonic Cancer Center, University of Minnesota (1) CASI pharmaceuticals (1) Sanofi (1) Celltrion (1) Mayo Clinic (1) GSK (1) Sinocelltech (1) Mao Jianhua (1) Institute of Hematology & Blood Diseases Hospital, China (1) EMN Trial Office S.r.l. Impresa Sociale (1)

Related targets

ROCK2 (1) ROCK1 (1) TNFSF4 (1) IL4R (1) GLP1R (1) Ion channels (1) OPRM1 (1) PDCD1 (1) CD274 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.